Point Guard Biosciences, LLC (PGBio) announced today, it is launching its inaugural PGBio Innovation in Ophthalmology Award. This award is created by PGBio to assist entrepreneurs in the area of ophthalmology with financial help as well as assistance with strategic planning.
“This award is focused on advancing innovative technologies currently in preclinical or early clinical stages of development that have clinical application in critical areas of ophthalmology” says Barry Butler, CEO of Point Guard Biosciences. “Ideal projects for this award could include new drug delivery systems, novel pharmaceutical products, innovative medical devices, new diagnostic tools, or technology to improve clinical trials”, he adds.
The award recipient will be chosen based on the novelty and power to advance medical research, and improve patient’s quality of life. The winner will be awarded a cash prize of $10,000. In addition to the cash prize, the award recipient will receive assistance by the PGBio team with the development of a business plan.
The submission deadline for this award is January 22nd 2016. The Award recipient will be announced on April 21st 2016.
Disclaimer: The decision of Point Guard Biosciences pertaining to the award recipient is final. Applicants must have all necessary rights and full authority pertaining to the intellectual property contained in order for their application to be valid.
TERMS AND CONDITIONS: Applications are due by January 22, 2016. Of the applications submitted by the deadline, one winner will be selected by Point Guard Biosciences LLC, to be announced April 21, 2016. The winner will be contacted according to the contact information submitted in the application. If a contestant's contact information changes after the submission of his/her application, but before the winner has been selected, it is the contestant's responsibility to inform Point Guard Biosciences LLC of the change. The winner will receive a $10,000 (USD) cash prize as well as a free, non-confidential business plan created by Point Guard Biosciences LLC (to be based upon the information and materials submitted as part of the application). Participation in the Innovation in Ophthalmology Award contest in no way construes a business relationship of any kind with Point Guard Partners LLC, or any of its subsidiaries or affiliates, including, but not limited to, Point Guard Biosciences LLC. All materials and information submitted to Point Guard Biosciences LLC as part of the application process are to be non-confidential and assumed to be part of the public domain. Applicant and Point Guard Biosciences LLC have not exchanged, and will not exchange, as part of this contest, any confidential information or materials, and Point Guard Biosciences LLC is under no obligation to protect said information or materials.
Ali joined NEA in 2007 and is a Partner on the healthcare team. He specializes in investments in the biopharmaceutical, medical device, specialty pharmaceutical and healthcare services sectors. Prior to joining NEA, Ali worked as an intern and later as a consultant in business development at The Medicines Company, a specialty pharmaceutical company developing acute care cardiovascular products. He previously held positions as a Venture Associate at Morgan Stanley Venture Partners and as a Healthcare Investment Banking Analyst at Lehman Brothers. He conducted basic science research in the fields of viral fusion inhibition and structural proteomics at the National Institutes of Health and at Duke University. Ali concurrently earned his MD degree from The University of Pennsylvania School of Medicine and his MBA degree from The University of Pennsylvania Wharton School, where he graduated with Honors and was a Palmer Scholar. He graduated summa cum laude and received his bachelor’s degrees with distinction in Biomedical Engineering, Electrical Engineering and Chemistry from Duke University.
Pierre-Paul Elena, recognized expert within the international community of ophthalmology and major stakeholder in the sector, has focused his 35-year career on encouraging excellence in ophthalmology. After defending his thesis successfully and a first position as a researcher in the basic research department of Allergan, Pierre-Paul Elena went on to create and develop several successful companies including Iris Pharma, which he managed for 26 years. This unique company, with a current workforce of 80 employees, intervenes at various drug development levels in the field of ophthalmology. Driven by Pierre-Paul Elena, Iris Pharma can pride itself on having been a key player in bringing nearly 70 ophthalmological drugs and medical devices to the market around the world. Pierre-Paul Elena is now both Chairman of the Supervisory Board and Chief Scientific Officer of Iris Pharma and serves as an expert to numerous pharmaceutical laboratories and biotechnology firms. Pierre-Paul Elena has authored or co-authored over 200 scientific articles and papers. He is the president and founding member of the Ophta Biotech association and a member of numerous associations in the field of ophthalmology including ARVO.
Gary D. Novack, Ph.D. is the founder and president of PharmaLogic Development, Inc. PharmaLogic is a consultancy providing development expertise to pharmaceutical and medical device companies. PharmaLogic specializes in ophthalmology and other local therapies. Dr. Novack studied at University of California campuses (BA from UC Santa Cruz, PhD in Pharmacology and Toxicology from UC Davis, and postdoctoral fellowship in neurophysiology at UCLA). He has worked in research positions at Merrell Dow, Allergan, and Nelson Research. He earned his diplomate in clinical pharmacology in 1990, the inaugural year of the certification. He has authored over 235 papers, and played a key role in the approval of over 40 products. Dr. Novack is on the editorial board of several ophthalmology journals, served in leadership roles in the Association for Research in Vision and Ophthalmology and the American Society for Clinical Pharmacology and Therapeutics. He was a member of DEWS, and is chairing a sub- committee for DEWS II. He was recognized by the American Academy of Ophthalmology with an Achievement Award in 2007. Dr. Novack is a UC Regent Emeritus, past president of the UC Santa Cruz Alumni Association and past president of the UC Santa Cruz Foundation. He is a Visiting Professor of Pharmacology and Ophthalmology at the University of California, Davis, School of Medicine.